Volume s1-31, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


At the beginning of 1948 a supply of a new synthetic antimalarial became available. This drug, amodiaquin (Camoquin Hydrochloride) is 4(3′-diethylamino-methyl-4′-hydroxyanilino)-7-chloroquinoline dihydrochloride dihydrate. It is a light yellow, crystalline powder which forms a 5 per cent solution in water at room temperature. It was first reported at the meeting of the American Chemical Society by Burckhalter . (1) in 1946. Its toxicity and tolerance have been determined by the parent laboratory, and it has been studied clinically (2, 3, 4, 5, 6, 7, 8, 9, 10) in numerous countries.

La Paz, Bolivia, where this study was conducted offers a fortunate combination of circumstances for a therapeutic evaluation of an antimalarial. Due to the cool climate and the altitude no vectors of the disease exist, thus there is no danger of reinfections contaminating the resulting follow-up observation. Second, the altitude increases the tendency of a dormant case of malaria to relapse.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error